Important Information for Pacira BioSciences, Inc. (PCRX) Investors: Rosen Law Firm Announces Lead Plaintiff Deadline in Securities Class Action
NEW YORK, March 06, 2025
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”), of the important March 14, 2025 lead plaintiff deadline in the securities class action filed in the United States District Court for the Eastern District of New York. The complaint alleges that defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that:
- Defendants were failing to properly manage their inventory levels, leading to excess inventory and increased costs;
- Defendants were experiencing declining sales due to increased competition and pricing pressures;
- Defendants were experiencing manufacturing issues with their Exparel product, including supply chain disruptions;
- Defendants were experiencing increased regulatory scrutiny and potential fines;
As a result of this information being revealed, the price of Pacira BioSciences, Inc. common stock declined significantly, causing harm to investors.
What Does This Mean for Individual Investors?
If you purchased Pacira BioSciences, Inc. securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline for this class action is March 14, 2025. The lead plaintiff is the investor who proposes a plan of action on behalf of the class. If you wish to act as lead plaintiff, you must apply to the Court no later than March 14, 2025. If you wish to join the litigation as a class member, you must provide your information by March 14, 2025 to be eligible for potential recovery.
What Does This Mean for the World?
The securities class action against Pacira BioSciences, Inc. is just one example of the importance of transparency and accurate reporting in the business world. When companies fail to disclose important information to investors, it can lead to significant financial losses and damage to the reputation of the company. This, in turn, can impact the broader market and the economy as a whole. It is crucial for companies to maintain the trust of their investors and the public by providing honest and accurate information.
Additionally, this case highlights the role of investor rights law firms in protecting the interests of individual investors. These firms help ensure that companies are held accountable for their actions and that investors are fairly compensated for any losses they have suffered.
Conclusion
If you purchased Pacira BioSciences, Inc. securities during the Class Period, it is important that you take action before the March 14, 2025 lead plaintiff deadline. The securities class action against the company is an important reminder of the need for transparency and accurate reporting in the business world. It is also a testament to the role of investor rights law firms in protecting the interests of individual investors.
For more information, please contact Laurence Rosen, Esq. or Philip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
From their offices in New York, the firm is actively involved in researching and investigating securities fraud schemes, reporting on suspected violations of securities laws, and prosecuting securities fraud class actions and shareholder derivative litigation against companies and their officers and directors. Rosen Law Firm has recovered hundreds of millions of dollars for investors.
For more information about the firm, please visit
DISCLAIMER: Rosen Law Firm P.A. announces that it is investigating potential securities fraud claims against Pacira BioSciences, Inc. on behalf of purchasers of the Company’s securities during the Class Period. The information provided herein constitutes only a notice of the pendency of an investigation, and no class has been certified in any way. The investigation is not pres presupposing the merit of your claim. If you wish to join the litigation, please provide your information by contacting Rosen Law Firm as described above.
